1.What is the objective and hypothesis of this article ? 2.What problem were the

Question

1.What is the objective and hypothesis of this article ? 2.What problem were they trying to solve? 3.A description of the system biology approach they took? 4.What are the results and findings? (Explain two figures as well) 5.What does the findings mean in term of the objective of the study? What is the take home message? Does the conclusion make sense?
Tumor molecular profiling of NSCLC patients using next generation sequencing NIKOLAOS TSOULOS', EIRINI P GEORGIOS TSAOUSIS', CHRISOULA EFSTATHIADOU!, GEORGIA TOUNTA, AIKATERINI SCAPET EUGENIA BOURKOULA PAVLOS ZAROGOULIDIS?, GEORGE PENTHEROUDAKIS STYLIANOS KAKOLYRIS', IOANNIS BOUKOVINAS, PAVLOS PAPAKOTOULAS ELIAS ATHANASIADIS, THEOFANIS FLOROS, ANNA KOUMARIANOU VASILEIOS BARBOUNIS1O, ANCA DINISCHIOTUI and GEORGE NASIOULAS APADOPOULOU, VASILIKI METAXA MARIATOU GeneKor Medical S.A. Athens 15344; 2Pulmonary Department, Oncology Unit, 'G.Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki $4124, Department of Medical Oncology. University Hospital of loannina, loannina 45500: "Department of Medical Oncology, University General Hospital of Alexandroupoli Alexandroupoli 68100, Medical Oncology, Bioclinie' of Thessaloniki, Thessaloniki 54622 "Second Department of Medical Oncology, Theagenion Anticancer Hospital of Thessaloniki Thessaloniki 54639·Department of Medical Oncology, Mitera Hospital, Athens 15123, 'Athens Naval and Veterans Hospital, Athens11521; Hematolog-Oacology Unit, Fourth Department of Intermal Medicine, Atikon Hospital, National and Kapodistrian Univensity of Athens, Athens 12462;10Third Medical Oncology Department, Metropolitan' Hospital, Pireas 18547,Greece, " Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Bucharest, Bucharest 0050095, Romania Received March 30, 2017; Accepted October 5, 2017 DOI: 10.3892/or.2017.6051 Abstract. Noa-small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with a broad spec- trum of targeted therapies already available or in clinical trials. Thus, molecular characterization of the tumor using cancer-driver gene were identified (inclading point mutations, gene rearrangements and MET amplifications) in 776% of the tumors tested Among the NSCLC patients, 23% presented a mutation in a gene associated with approved or emerging targeted therapy. More specifically, 135% (685020 presented a mutation in a gene with approved targesed therapy (EGFR, key tool for facilitating managemenior NSCLC Patient, The perforrnance of a ALK, ROSI) and 9,4% (471502) had an alteration in a gene custom 23 gene multiplex amplification hot spot panel, based related to emerging targeted therapies (ERBB2, BRAF, MET on lon AmpliSeq™ technology, was evaluated for the analysis and RET Furthermore, si 6% of the patients had mutation of tumor DNA extracted from formalin-fixed and paraffn. in a gene that could be related to an off label therapy or indica embedded (FFPE) tissues. Furthermore, the lon AmpliSeqtive for access to a clinical trial. Thus, the targeted NGS panel RNA Fusion Lung Cancer Research Panel was used for used in this study is a reliable approach for tumexr molecular fusion RNA transcript analysis. The mutation spectrum of profiling and can be applied in personalized treatment deci- the tumors was determined in a cobort of 502 patients with sion making for NSCLC patients NSCLC using the aforementioned targeted gene panels. The panel used for tumor DNA analysis in this study exhibited Introduction high rates (100%) of sensitivity, specificity and reproducibility at a mutation allelic frequency of 3%. At least one DNA muta- Lung canceristheprimaocausedcance associated tion was detected in 374 patients (745%) and an RNA fusion rtottatoworldwideinmenandahesecond leading( was identified in 16 patients, (32%). In total, alterations in a deancenrelated deathnwa mah The man type of lung and the clinigal cancer is non-small cell lfung cancer (NSCLC) which accounts for-85% of all lung cancer cases Treatment options for lung cancerinclude surgery,radiation Although chemotherapy remains Correspondence to: Dr George Nasioulas, GeneKor Medical S.A. 52 Spaton Avenue, Gerakas, Athens 15344, Greece E-mail: gnasioulas@genekor.com an important form of treatment, novel drug development has focused oa molecular-targeted therapies. The effectivesess of such targeted therapies rely on the presence or absence of alterations in gene(s) that encode for the protein targeted by the agent or for proseins involved in the molecular pathway ng, non-small cell lung cancer, predictive markers, targeted therapy targeted (3).

Explanation / Answer

ANSWER:

Related Questions

Navigate

• Browse (All)
• Browse 1
• Subjects

---

---

Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.